Sellas Life Sciences Group Inc
NASDAQ:SLS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 11 full-time employees. The company went IPO on 2008-03-12. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.
Pipeline Progress: SELLAS advanced late-stage clinical programs, including initiating a pivotal Phase III trial for GPS in AML and progressing a Phase I/II basket trial with Merck's Keytruda.
Positive NPS Data: Final Phase IIb data for NPS (NeuVax) in triple negative breast cancer showed a significant reduction in relapse or death risk and robust safety, supporting further FDA engagement.
Financial Strength: Raised approximately $22 million in equity and added $6.6 million from a litigation settlement, eliminating all company debt and supporting ongoing operations.
Cash Runway: Management reiterated that cash and equivalents are sufficient to fund operations through at least March 2019.
Regulatory and Partnerships: Active discussions with the FDA and potential partners for NPS, with an important FDA meeting set for December.
Expense Trends: Increased R&D expenses due to clinical trial activity, but overall cost control and expense guidance will be updated with Q4 results.
